Original research studies and deep-dive analyses.

198 FDA approvals. Eleven traits, most of them fixed before approval, separate launches that tend to beat their forecast from launches that tend to miss.

Four structurally different futures for the U.S. market in 2035, and what each one changes about turning a medicine into a viable business.
Occasional, launch-focused, worth opening. Unsubscribe anytime. Or follow the RSS feed.
From a specific launch to broader portfolio and organizational questions.
Request a Futures Briefing